Partial cellular reprogramming employs Yamanaka factors to shift aging cells toward a younger epigenetic state without compromising cellular identity. Over two decades, this Nobel Prize winning breakthrough has advanced from the bench to a first in-human trial in 2026 for optic neuropathy and glaucoma. Here, we outline the foundation of partial cellular reprogramming and delineate its intersection with our field. Defined by innovation, plastic surgery can shape how partial reprogramming is applied in what may prove to be a transformative chapter for our specialty.
No takes yet. Share an insight, caveat, or question.
Mahmoud et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: